These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9476844)

  • 1. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
    Torphy TJ
    Am J Respir Crit Care Med; 1998 Feb; 157(2):351-70. PubMed ID: 9476844
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cyclic nucleotides phosphodiesterases inhibitors].
    Hagiwara M; Hidaka H
    Nihon Rinsho; 1991 Sep; 49(9):1993-8. PubMed ID: 1660084
    [No Abstract]   [Full Text] [Related]  

  • 3. [Regulation of the phosphodiesterase activity of cyclic nucleotides (new endogenous regulators)].
    Galoian AA; Gurvits BIa
    Vestn Akad Med Nauk SSSR; 1982; (9):64-9. PubMed ID: 6293217
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemical evolution of autotaxin inhibitors.
    Albers HM; Ovaa H
    Chem Rev; 2012 May; 112(5):2593-603. PubMed ID: 22335786
    [No Abstract]   [Full Text] [Related]  

  • 5. Ginsenosides are potent and selective inhibitors of some calmodulin-dependent phosphodiesterase isozymes.
    Sharma RK; Kalra J
    Biochemistry; 1993 May; 32(19):4975-8. PubMed ID: 8388250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and kinetic properties of cardiac calmodulin dependent cyclic nucleotide PDE (PDE-I).
    Clapham JC; Wilderspin AF
    Biochem Soc Trans; 1996 May; 24(2):320S. PubMed ID: 8736978
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V
    Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapeutic potential of phosphodiesterase inhibitors.
    Perry MJ; Higgs GA
    Curr Opin Chem Biol; 1998 Aug; 2(4):472-81. PubMed ID: 9736920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated cAMP-phosphodiesterase in atopic disease: cause or effect?
    Townley RG
    J Lab Clin Med; 1993 Jan; 121(1):15-7. PubMed ID: 8381147
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic potential of selective PDE inhibitors in asthma.
    Schudt C; Gantner F; Tenors H; Hatzelmann A
    Pulm Pharmacol Ther; 1999; 12(2):123-9. PubMed ID: 10373395
    [No Abstract]   [Full Text] [Related]  

  • 11. Amantadine: an antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme.
    Kakkar R; Raju RV; Rajput AH; Sharma RK
    Brain Res; 1997 Feb; 749(2):290-4. PubMed ID: 9138729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent progress in cyclic nucleotide phosphodiesterase research: isozymes, functions, and inhibitors].
    Kotera J; Sasaki T; Omori K
    Nihon Yakurigaku Zasshi; 2005 Aug; 126(2):121-7. PubMed ID: 16205015
    [No Abstract]   [Full Text] [Related]  

  • 14. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
    Gupta R; Kumar G; Kumar RS
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phosphodiesterase 5--the enzyme inhibited by sildenafil (Viagra)].
    Sandberg M; Natarajan V
    Tidsskr Nor Laegeforen; 1999 Mar; 119(7):945-9. PubMed ID: 10210955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.
    Torphy TJ; Undem BJ; Cieslinski LB; Luttmann MA; Reeves ML; Hay DW
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1213-23. PubMed ID: 8389856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase inhibitors: knockout drops?
    Raeburn D; Karlsson JA
    J Pharm Pharmacol; 1997 May; 49 Suppl 3():19-24. PubMed ID: 9178203
    [No Abstract]   [Full Text] [Related]  

  • 18. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.
    Shakur Y; de Koning HP; Ke H; Kambayashi J; Seebeck T
    Handb Exp Pharmacol; 2011; (204):487-510. PubMed ID: 21695653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
    Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
    J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.